Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis-Reference-Cited by-同舟云学术

Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis

Published:2023-07 Issue:4 Volume:35 Page:206-217
ISSN:0214-9168
Container-title:Clínica e Investigación en Arteriosclerosis
language:es
Short-container-title:Clínica e Investigación en Arteriosclerosis

Author:

Pintó Xavier,Fanlo Marta,Esteve Virginia,Millán Jesús,Blanco Agustín,Blasco Mariano,Díaz Díaz José Luís,Díaz Rodríguez Ángel,Mangas Alipio,Pascual Vicente,Pedro Botet Juan,Pérez Martínez Pablo

Funder

Institut Catala De La Salut

Publisher

Elsevier BV

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

Reference79 articles.

1. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS);Mach;Eur Heart J,2020

2. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Grundy;J Am Coll Cardiol,2019

3. SEA 2022 standards for global control of cardiovascular risk;Mostaza;Clin Investig Arterioscler,2022

4. Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174,000 participants in 27 randomised trials;Fulcher;Lancet,2015

5. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials;Baigent;Lancet,2010

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increasing the complexity of lipoprotein characterization for cardiovascular risk in type 2 diabetes;European Journal of Clinical Investigation;2024-04-13

2. Comparative analysis of neutrophil-to-lymphocyte ratio and remnant cholesterol in predicting cardiovascular events and mortality in general adult population;Scientific Reports;2023-12-15

3. Pemafibrate: PROMINENT failure or an urgent need for therapeutic replacement?;Clínica e Investigación en Arteriosclerosis (English Edition);2023-07